Arnold Greenberg, MD
Neurology · San Francisco, CANPI 1780616177
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 747 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,577 and has fallen 54.3% since, to $1,636 in 2025.
Across 747 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- UCB, Inc.$2K
- AbbVie$2K
- SK Life Science, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Eisai Inc.$811
- plus $10K from 44 others
What the payments were for
- Speaking & faculty fees$200%
- Food & beverage$17,88999%
- Education$2131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,122 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 133 | $132,023 |
| Emgality PenGalcanezumab-Gnlm | 113 | $124,508 |
| Nurtec OdtRimegepant Sulfate | 53 | $77,406 |
| GraliseGabapentin | 52 | $60,873 |
| Ajovy SyringeFremanezumab-Vfrm | 36 | $34,799 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $28,662 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $28,346 |
| ExelonRivastigmine | 30 | $22,722 |
| HorizantGabapentin Enacarbil | 19 | $21,773 |
| BelsomraSuvorexant | 34 | $14,828 |
| UbrelvyUbrogepant | 14 | $12,544 |
| Memantine Hcl ErMemantine Hcl | 65 | $11,278 |
| ZtlidoLidocaine | 23 | $8,123 |
| Lidocaine | 55 | $5,659 |
| Gabapentin | 488 | $5,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $601 | $77,40653 claims |
| Almatica Pharma LLCGralise, Sertraline Hcl | $206 | $61,02889 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $627 | $28,34618 claims |
| NovartisExelon | $177 | $22,72230 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $245 | $21,77319 claims |
| MerckBelsomra | $141 | $14,82834 claims |
| AbbVieUbrelvy | $1,519 | $12,54414 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $183 | $8,12323 claims |
| Upsher-smith Laboratories LLCTopiramate | $96 | $979120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.